Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Non-randomized Phase II Trial of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Who Meet Criteria for Late Suboptimal Response After Prior Imatinib Treatment

NCT01802450 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT01802450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01802450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Non-randomized Phase II Trial of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Who Meet Criteria for Late Suboptimal Response After Prior Imatinib Treatment
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2013
Completion date
December 31, 2016
Enrollment
18 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia